These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 2388647)

  • 21. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 22. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease.
    Obeso JA; Luquin MR; Martínez-Lage JM
    Lancet; 1986 Mar; 1(8479):467-70. PubMed ID: 2869209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F; Vacca L; Ruggieri S; Olanow CW
    Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
    Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
    Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
    Nyholm D
    Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lisuride infusion pump in Parkinson's disease. A report of two cases.
    Gershanik OS; Scipioni O; García S
    J Neural Transm Suppl; 1988; 27():85-90. PubMed ID: 2969955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 33. A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
    Chouza C; Caamaño JL; de Medina O; Aljanati R; Scaramelli A; Romero S
    J Neural Transm Suppl; 1988; 27():61-70. PubMed ID: 3042913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One year treatment with lisuride delivery pump in Parkinson's disease.
    Ruggieri S; Stocchi F; Carta A; Bragoni M; Agostini C; Barbato L; Agnoli A
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):173-83. PubMed ID: 2748858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous subcutaneous lisuride infusions in Parkinson's disease.
    Critchley PH; Grandas Perez F; Quinn NP; Parkes JD; Marsden CD
    J Neural Transm Suppl; 1988; 27():55-60. PubMed ID: 2969953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.